OBLN vs. BJDX, NMRD, SINT, AFIB, DYNT, RSLS, AEMD, LLIT, GMVDF, and OSAP
Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Bluejay Diagnostics (BJDX), Nemaura Medical (NMRD), Sintx Technologies (SINT), Acutus Medical (AFIB), Dynatronics (DYNT), ReShape Lifesciences (RSLS), Aethlon Medical (AEMD), Lianluo Smart (LLIT), G Medical Innovations (GMVDF), and ProSomnus (OSAP). These companies are all part of the "medical" sector.
Bluejay Diagnostics (NASDAQ:BJDX) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.
Obalon Therapeutics received 244 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 50.93% of users gave Obalon Therapeutics an outperform vote.
Bluejay Diagnostics has a net margin of 0.00% compared to Bluejay Diagnostics' net margin of -776.76%. Bluejay Diagnostics' return on equity of -161.38% beat Obalon Therapeutics' return on equity.
18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are held by institutional investors. 17.6% of Bluejay Diagnostics shares are held by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Obalon Therapeutics' average media sentiment score of 0.00 equaled Bluejay Diagnostics'average media sentiment score.
Bluejay Diagnostics has higher earnings, but lower revenue than Obalon Therapeutics.
Bluejay Diagnostics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500.
Summary
Bluejay Diagnostics beats Obalon Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Obalon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Obalon Therapeutics Competitors List
Related Companies and Tools
